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ABSTRACT
Introduction: A large-scale clinical trial, the
Sequence Trial Alternatives to Relieve
Depression (STAR*D) study, concluded that
about one-third of the studied patients with
major depressive disorder remitted during the
initial treatment with selective serotonin
reuptake inhibitors and that approximately half
of the remitted subjects relapsed over a 1-year
follow-up. The development of new therapeutic
approaches with potent efficacy and good
tolerability for the treatment of depressive
disorders is of great importance. Adult
hippocampal neurogenesis has been proposed to
be important for understanding and treating
depression and anxiety. The present study aimed
to elucidate whether or not 5-hydroxytryptamine
1A (5-HT1A) receptor partial agonists have a
potential therapeutic effect for the treatment of
depressive and anxiety disorders, from the
standpoint of neurogenesis.
Methods: Male Sprague–Dawley rats were
subcutaneously administered a vehicle or
tandospirone (TDS) (1 or 10 mg/kg) once daily
for 14 days. The effects of chronic TDS treatment
on neurogenesis were evaluated on the day after
the last injection. The quantification of
hippocampal neurogenesis was estimated using
immunostaining with doublecortin (DCX), a
marker protein of newborn neurons.
Results: Chronic TDS treatment resulted in a
significant increase in the number of DCX-
positive cells per volume of dentate gyrus in a
dose-dependent manner.
Conclusion: The results strongly suggest that
5-HT1A receptor partial agonists would be
useful and beneficial in the treatment of
depressive and anxiety disorders through
increased hippocampal neurogenesis.
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INTRODUCTION
Depression and anxiety are common public
health problems, affecting 5–10% of the
world’s population at any given time, and
they share a high degree of comorbidity (up to
80–90%) [1]. Although there are a number of
medications available for the treatment of
depressive and anxiety disorders, a
considerable number of patients cannot
achieve remission [2]. The Sequenced
Treatment Alternatives to Relieve Depression
(STAR*D) study, a large-scale clinical trial for
major depressive disorder (MDD), demonstrated
that only about one-third of the participants
remitted during the initial treatment with
citalopram and that approximately half of the
remitted participants relapsed over a 1-year
follow-up [3–5]. Baldwin et al. [6], in a review
of previous studies of pharmacotherapies for
generalized anxiety disorder (GAD), concluded
that the remission rate is less than 60% for GAD
patients treated with selective serotonin
reuptake inhibitors (SSRIs). Therefore, the
development of effective new therapeutic
approaches with good tolerability for the
treatment of depressive and anxiety disorders
is of great importance.
Adult hippocampal neurogenesis has been
proposed as important for understanding and
treating depression and anxiety [7]. The
hippocampus is not only involved in cognitive
functions, but also is a key structure for
regulating affective and anxiety states. The
subgranular zone (SGZ) in the dentate gyrus
(DG) of the hippocampus is one of only a few
brain regions where the production of new
neurons occurs throughout the lifetime of
animals, including humans [8, 9].
Accumulating evidence shows that adult
hippocampal neurogenesis is decreased by
stress and increased by chronic administration
of antidepressants, such as fluoxetine [10, 11].
Thus, changes in adult hippocampal
neurogenesis may be related to the
pathophysiology of depressive and anxiety
disorders and to the beneficial effects of
antidepressant treatment [7, 9, 12, 13].
The azapirone drugs, including buspirone,
tandospirone (TDS), and gepirone which act as
5-hydroxytryptamine 1A (5-HT1A) receptor
partial agonists, have been widely used in the
treatment of anxiety disorder [14, 15]. In
practice, benzodiazepines are most frequently
used in combination with standard
antidepressants for the initial treatment and
maintenance therapy for depressive disorders
when comorbid anxiety exists [16]. We and
many other researchers have shown that
benzodiazepines produce drug dependence,
sedation, and cognitive impairment in
humans and rodents [17–20]. In contrast,
azapirone-type 5-HT1A receptor agonists have
the advantage of producing significantly fewer
adverse effects than benzodiazepines and result
in little dependence [21–23]. Recently, two
animal studies revealed that co-administering
benzodiazepines with antidepressants prevents
an SSRI-induced increase in hippocampal
neurogenesis, which suggests that the use of
benzodiazepines delays the therapeutic onset
and reduces the clinical efficacy of SSRIs [24,
25]. In contrast to above reports concerning
benzodiazepines, 5-HT1A receptor agonists are
considered to have an augmenting effect on
clinical efficacy for depressive disorders when
administered in combination with an SSRI.
Recently, several authors have reported that
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augmentation therapy consisting of a
combination of antidepressants with 5-HT1A
receptor agonist treatment is a better
therapeutic strategy for MDD than
antidepressant monotherapy [3, 26, 27].
In our previous pilot study, we showed that
TDS, the only azapirone drug available in Japan,
has excellent clinical efficacy for the treatment
of GAD and mixed anxiety–depression and that
it has no significant adverse effects [28]. We also
showed that TDS had a remarkable anxiolytic
effect in an animal model of anxiety and that
the potency of the pharmacological effect was
increased dose dependently, without a sedative
effect [23].
In addition, we conducted a preliminary
clinical study about the efficacy of
augmentation therapy consisting of a
combination of paroxetine and TDS
(Sakamoto et al., unpublished data). In that
study, among a consecutive series of 37
patients with MDD who were treated with
the combination of paroxetine and TDS, 29
subjects (78.4%) achieved remission at
12 weeks after the start of treatment.
Furthermore, our 4-year follow-up study
found recurrence in only 5 (17.9%) of 28
patients who had remitted.
Thus, 5-HT1A receptor partial agonists,
clinically available and safe drugs, may have
great usefulness in the treatment of psychiatric
illness, such as depression and anxiety.
It is well known that 5-HT1A receptors play
an important role in the regulation of mood,
anxiety, and cognition [15]. 5-HT1A receptors
also have been shown to regulate hippocampal
neurogenesis in the SGZ of the DG. Santarelli
et al. [29] showed that 5-HT1A receptor-
deficient mice did not respond to chronic
fluoxetine treatment, as measured by the
change in neurogenesis. Reporting on the
effect of 5-HT1A receptor agonists on
neurogenesis, Banasr et al. [30] and Soumier
et al. [31] showed increased granule cell genesis
in the DG during treatment with 8-hydroxy-2-
dipropylaminotetralin hydrobromide (8-OH-
DPAT), a 5-HT1A receptor full agonist.
However, 8-OH-DPAT is a chemical reagent
that is not available for clinical use. Of
interest, Radley and Jacobs [32] reported that
the acute administration of 5-HT1A receptor
full antagonist WAY100635 decreased
neurogenesis in the DG.
Based on previous reports by many authors
and our studies described above, we
hypothesize that hippocampal neurogenesis
plays an important role in the clinical efficacy
of 5-HT1A receptor partial agonists.
This study aimed to elucidate the potential
therapeutic effect of 5-HT1A receptor partial
agonists in the treatment of depressive and




Male Sprague–Dawley rats (Kyudo Co., LTD.,
Tosu, Japan) weighing 150–200 g upon arrival
were studied. They were housed individually in
a temperature (23 ± 2 C), humidity
(60 ± 10%), and light-controlled room (reverse
12-h light/dark cycle, lights off at 7:00 a.m.).
Food and water were available ad libitum. All
animal care and use procedures were performed
in compliance with the regulations established
by the Experimental Animal Care and Use
Committee of Fukuoka University, which are
in accordance with the universal principles of
laboratory animal care.
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Drugs
Tandospirone citrate was supplied by
Dainippon Sumitomo Pharma Co., Ltd.
(Osaka, Japan). The drug was dissolved in
saline and prepared at a concentration of 1 or
10 mg/mL, then injected subcutaneously in a
volume of 1 mL/kg. The control animals were
given the same volume of vehicle solution. The
dosage of TDS was chosen on the basis of
previous reports [23, 33]. One week following
the arrival of the animals at the laboratory, they
were injected with either the vehicle or TDS (1
or 10 mg/kg) once daily for 14 days.
Novelty Suppressed Feeding (NSF) test
Novelty Suppressed Feeding test was performed
as previously described [34–36]. Briefly, animals
were fasted for 24 h, then placed in a corner of a
large polypropylene tub (50 9 40 9 20 cm) with
a food pellet positioned in the center. The time
to the first chewing of the food (latency) was
recorded. The test was continued for 12 min
and if the animal had not eaten the result was
scored as 12 min. To evaluate the acute effect of
TDS, the rats were initially injected with the
vehicle or TDS, then 20 min later subjected to
the first NSF test. In the experiment
investigating the chronic effect of TDS, drug
treatment was done for 14 days, and the next
day the rats were subjected to the second NSF
test.
Brain Slice Preparation
Two hours after termination of the second NSF
test, the rats were deeply anesthetized with
sodium pentobarbital and perfused
transcardially with saline (1,000 mL/kg)
followed by 250 mL of 4% ice-cold
paraformaldehyde in 0.1 M phosphate buffered
saline (PBS; pH 7.4). The brain was removed
from the skull and post-fixed overnight in the
same fixative at 4 C, then placed into graded
concentrations of sucrose in PBS at 4 C.
Coronal sections of the brain were cut (30 lm
sections) through the entire hippocampus
(bregma -1.72 to -6.84 mm [37]) on a
freezing microtome. Sections were mounted
onto silane-coated glass slides, then dried and
stored at -80 C prior to processing.
Immunohistochemistry
After washing in PBS, sections were incubated
for 30 min in 3% H2O2 to eliminate endogenous
peroxidases. After blocking with 5% normal
goat serum, the sections were incubated with
anti-doublecortin (DCX) primary antibody
(rabbit, 1:1,000; Abcam, Cambridge, UK)
overnight at 4 C. They were then incubated
for 2 h with secondary antibody (biotinylated
goat anti-rabbit, 1:200; Vector Laboratories,
Burlingame, CA, USA) followed by
amplification with an avidin–biotin complex
(1:300; DAKO Japan, Kyoto, Japan), and the
cells were visualized with diaminobenzidine
(DAB) (Vector Laboratories, Burlingame, CA,
USA). The sections were air-dried and
counterstained with hematoxylin, then
dehydrated, cleared in xylene, and
coverslipped.
Stereological Analysis of DCX-Positive
Cells in DG
The total number of DCX-positive cells was
counted throughout the rostrocaudal extent of
the DG of granule cell layer (GCL) using a 409
objective (Nikon E600, Nikon, Tokyo, Japan).
The optical fractionator method was used for
counting, as previously described with minor
modifications [30]. Briefly, in every section, the
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contour of the GCL/SGZ was first delineated for
counting using the tracing function of the
StereoInvestigator (MicroBrightField Japan,
Chiba, Japan) software. Following this, the
optical fractionator component was activated
by entering parameters such as the grid size, the
thickness of the guard zone, and the optical
dissector height. A computer-driven motorized
stage then randomly determined the counting
frame locations. The StereoInvestigator software
used the optical fractionator formula to
calculate the total number of DCX-positive
cells per DG. Every eighth section throughout
the DG was analyzed, yielding a mean of 20
sections per brain. The total number of DCX-
labeled cells in the GCL together with the SGZ,
which is defined as a two-cell-body-wide zone
along the border of the GCL, was estimated.
This procedure ensured a systematic random
sample of the sections, in which all parts of the
DG region analyzed had the same opportunity
of being represented. The precision of estimates
of the number of cells was expressed using the
coefficient of error (CE). The stereological
sampling scheme was considered adequate
when CE was less than 0.10 [38].
Statistical Analysis
One-way factorial analysis of variance (ANOVA)
was performed to test for differences in latency
in the NSF test and for quantification of DCX-
positive cells, followed by Bonferroni/Dunn
post hoc analysis for further examination of
group differences. For the NSF test, the Kaplan–
Meier method with Mantel–Cox log-rank test
was used to determine differences in survival
curves where the latency to eat was the limit of
survival as previously described [25]. All data are
represented as mean ± standard error of the
mean (SEM). P value of \0.05 was adopted for
significance.
RESULTS
The Effects of Tandospirone in the NSF test
The acute effect of TDS in the NSF test was
examined immediately after the first injection
of vehicle or TDS. TDS-treated animals
performed significantly better than the
vehicle-treated group (Kaplan–Meier survival
analysis, Mantel–Cox log-rank test, P = 0.0145;
Fig. 1a, One-way ANOVA, F2, 10 = 5.753,
P = 0.0217; Fig. 1b). Post hoc analysis further
showed that acute treatment with high-dose
TDS (10 mg/kg) produced a significant decrease
in the latency to feeding relative to the vehicle-
(P = 0.0080) and TDS (1 mg/kg)-treated rats
(P = 0.0370). On the contrary, chronic TDS
treatment did not have any behavioral effect
on the latency to feeding compared with the
vehicle-treated group (Fig. 1c, d).
The Effects of Tandospirone on DCX-
Positive Cells in the Dentate Gyrus
of the Hippocampus
Because of technical problems, brain samples
for immunohistochemistry analysis could not
be taken from three animals (one vehicle-
treated group, one TDS 1 mg/kg-treated group
and one TDS 10 mg/kg-treated group). DCX is a
protein expressed in immature newly born
neurons that has recently been utilized to
assess the level of neurogenesis [39, 40]. To
assess the potential of TDS to modulate
hippocampal neurogenesis, the number of
DCX-immunopositive cells in the DG of the
hippocampus was evaluated. Representative
images of doublecortin-positive cells are
shown in Fig. 2. DCX-labeled cells were
observed mainly at the border of the GCL in
the DG of the hippocampus (Fig. 2). The
number of DCX-positive cells per volume of
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DG was significantly increased in the TDS-
treated group compared with the vehicle-
treated group (F2, 7 = 17.853, P = 0.0018;
Fig. 3). Post hoc analysis identified significant
differences between the vehicle-treated group
and both the low and high dosage TDS-treated
groups (P = 0.0155, P\0.001, respectively) and
between the TDS (1 mg/kg) and TDS (10 mg/
kg)-treated groups (P = 0.0368). However, no
significant relationships between the number of
DCX-labeled cells in the DG and the latency to
feeding in the NSF test were found in the
correlational analysis (data not shown).
DISCUSSION
In the present study, administration of TDS for
14 days increased the number of DCX-positive
cells in the DG of adult rat hippocampus in a
dose-dependent manner. This result suggests
Fig. 1 Effects of acute and chronic tandospirone (TDS)
treatment on the time to feeding (latency) in a Novelty
Suppressed Feeding (NSF) test. The results are expressed as
the cumulative survival of animals that have not eaten for
over 12 min (left panel) or as the mean latency to feeding in
seconds (right panel). The administration of TDS (10 mg/
kg) 20 min prior to testing resulted in a signiﬁcant
reduction in the latency to feeding compared with a
vehicle-treated group (a, b). However, no signiﬁcant
differences in the NSF test were observed between the
vehicle- and TDS-treated groups 24 h after 14 days of TDS
treatment (c, d). *P\0.05, **P\0.01 vs. vehicle-treated
group; #P\0.05 vs. TDS 1 mg/kg-treated group (Kaplan–
Meier survival analysis, Mantel–Cox log-rank test or one-
way ANOVA followed by Bonferroni/Dunn post hoc
analysis)
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that chronic treatment with TDS increases
hippocampal neurogenesis in humans, because
DCX can be used as a quantitative marker of
new nerve cells in the adult brain [39, 40]. Adult
hippocampal neurogenesis has been shown to
be important for understanding and treating
depression and anxiety [7]. Based on our result,
we propose that 5-HT1A receptor partial
agonists would be of great clinical usefulness
for the treatment of depressive and anxiety
disorders because of increased hippocampal
neurogenesis. However, it will also be
necessary in future studies to use other
markers, such as Ki-67, NeuroD or NeuN, at
each stage of neurogenesis and to assess the
maturation index and synaptic branching in
Fig. 2 Photomicrographs of doublecortin (DCX)-positive
cells in the dentate gyrus of the rat hippocampus after
chronic treatment (left, 940; right, 9100 of the boxed
region). DCX-positive cells were mainly located in the
subgranular zone (SGZ). Vehicle-treated group (a). TDS
1 mg/kg-treated group (b). TDS 10 mg/kg-treated group
(c). GCL granule cell layer, ML molecular layer (scale bars:
left, 50 lm; right, 10 lm)
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the hippocampal neurons to establish the
relationship between 5-HT1A activation and
the neurogenic effect on anxiolytic and
antidepressant response.
To our knowledge, this is the first report to
show chronic, positive effects of a 5-HT1A
receptor partial agonist, a clinically available
and safe drug, on hippocampal neurogenesis in
rodents. Several studies have reported
hippocampal neurogenesis using 5-HT1A
receptor agonists or antagonists that are
experimental reagents not available for clinical
use. Banasr et al. [30] and Soumier et al. [31]
found an increasing effect of 8-OH-DPAT, a
5-HT1A receptor full agonist, on granule cell
genesis in the DG of the hippocampus of
rodents, and Radley and Jacobs [32] reported
that the acute administration of 5-HT1A
receptor full antagonist WAY100635 decreases
neurogenesis in the DG of the hippocampus of
rodents. Further study will be necessary to
determine if the administration of 5-HT1A
receptor antagonists, such as WAY100635,
block the increase in neurogenesis induced by
chronic TDS administration.
The anxiolytic effect of 5-HT1A receptor
partial agonists has been established and it has
been shown that 5-HT1A receptor partial
agonists have no remarkable adverse effects
and little dependency. Furthermore, previous
clinical trials suggest the possibility of 5-HT1A
receptor partial agonists as useful drugs for the
treatment of schizophrenia, eating disorders,
Parkinson’s disease, and cognitive dysfunction
[41–46]. Recently, hippocampal neurogenesis
has been associated with the etiology and
treatment of neurodegenerative disorders, such
as Parkinson’s disease and Alzheimer’s disease
[47]. Also, Barbarich-Marsteller et al. [48]
reported that hippocampal cell proliferation in
the DG was reduced in an animal model of
anorexia nervosa. Our results suggest the
clinical usefulness of 5-HT1A receptor partial
agonists for the treatment of such important
diseases as those described above.
5-HT1A receptor partial agonists can also be
used as augmentation therapy in conjunction
with antidepressants for the treatment of
depressive disorder [3]. Recent animal studies
indicate that co-administering benzodiazepines
with antidepressants prevents the SSRI-induced
increase in hippocampal neurogenesis,
although benzodiazepines are often used as
anxiolytics in combination with
antidepressants for depressive disorders,
especially in the early phases of therapy when
comorbid anxiety is present [16, 24, 25]. In
contrast, our result suggesting that TDS
treatment induces an increase in hippocampal
neurogenesis helps explain the augmenting
effect of 5-HT1A receptor partial agonists on
their clinical efficacy for depressive disorders
when administered in combination with an
SSRI.
Fig. 3 Effects of chronic tandospirone (TDS) treatment
on doublecortin (DCX) positive cells per volume of
dentate gyrus (cells/mm3). The density of DCX-positive
cells was signiﬁcantly increased by treatment with TDS for
14 days compared with the vehicle-treated group. The
degree of increase in the density of DCX-positive cells
increased by chronic TDS treatment was dose-dependent.
*P\0.05, ***P\0.001 vs. vehicle-treated group;
#P\0.05 vs. TDS 1 mg/kg-treated group (one-way
ANOVA followed by Bonferroni/Dunn post hoc analysis)
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In the present study, acute treatment with
TDS significantly decreased the latency to
feeding in the NSF test. The NSF test assesses
anxiety behavior by measuring the time it takes
an animal to approach and eat a familiar food in
an aversive environment. Also, the NSF test is
considered to be very sensitive to chronic
treatment with antidepressants, including
SSRIs [35]. Although it is difficult to prove that
acute treatment with TDS exerts the same
anxiolytic effect as chronic antidepressant
treatment, this result suggests that TDS has
specific efficacy for anxiety disorders. We also
showed the anxiolytic effect of TDS using
conditioned fear stress-induced freezing
behavior in a previous study [23]. Thus, we
have shown the excellent anxiolytic effect of
TDS using two unique rodent models of anxiety
behavior.
Of interest, several studies have indicated
that there are relationships between
hippocampal neurogenesis and behavioral
changes in NSF testing of stress-exposed
animals [29, 49]. However, in the present
study, chronic treatment with TDS displayed
no significant differences in the time to
consumption of a food pellet in a NSF test,
despite the finding of a significant increase in
the number of DCX-positive cells. It will be
necessary to carry out further studies to explain
why this study failed to find behavioral change
in rats chronically administered TDS.
Restructuring of the experimental
methodology should be considered, including
changes in the duration of TDS administration,
increasing the sample size of rats chronically
administered TDS, and investigation of the
effects of TDS in NSF testing that uses models
of depressive animals exposed to stressors. In
addition, a forced swim test, a novel animal
model of depressive disorders, should be done
to clarify the effect on the behavioral change of
rats undergoing chronic TDS treatment.
CONCLUSION
In conclusion, this study strongly suggests that
5-HT1A receptor partial agonists are useful and
beneficial for the treatment of depressive and
anxiety disorders, from the standpoint of
hippocampal neurogenesis.
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